301 related articles for article (PubMed ID: 24354438)
1. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
Hallert E; Husberg M; Kalkan A; Skogh T; Bernfort L
Scand J Rheumatol; 2014; 43(3):177-83. PubMed ID: 24354438
[TBL] [Abstract][Full Text] [Related]
2. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
Hallert E; Husberg M; Skogh T
Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project).
Hallert E; Husberg M; Jonsson D; Skogh T
Rheumatology (Oxford); 2004 Nov; 43(11):1374-82. PubMed ID: 15280570
[TBL] [Abstract][Full Text] [Related]
4. 28-Joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project.
Hallert E; Husberg M; Skogh T
Rheumatology (Oxford); 2011 Jul; 50(7):1259-67. PubMed ID: 21292734
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09.
Hallert E; Husberg M; Kalkan A; Bernfort L
Scand J Rheumatol; 2016 Oct; 45(5):371-8. PubMed ID: 26854719
[TBL] [Abstract][Full Text] [Related]
6. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
Eriksson JK; Johansson K; Askling J; Neovius M
Ann Rheum Dis; 2015 Apr; 74(4):648-54. PubMed ID: 24323395
[TBL] [Abstract][Full Text] [Related]
7. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
[TBL] [Abstract][Full Text] [Related]
8. Costs and disease activity in early rheumatoid arthritis in 1996-2000 and 2006-2011, improved outcome and shift in distribution of costs: a two-year follow-up.
Husberg M; Bernfort L; Hallert E
Scand J Rheumatol; 2018 Sep; 47(5):378-383. PubMed ID: 29611446
[TBL] [Abstract][Full Text] [Related]
9. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
[TBL] [Abstract][Full Text] [Related]
11. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
Kvamme MK; Lie E; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
[TBL] [Abstract][Full Text] [Related]
12. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
Zhu TY; Tam LS; Li EK
Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
[TBL] [Abstract][Full Text] [Related]
13. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
[TBL] [Abstract][Full Text] [Related]
14. Sick leave before and after diagnosis of rheumatoid arthritis--a report from the Swedish TIRA project.
Björk M; Thyberg I; Rikner K; Balogh I; Gerdle B
J Rheumatol; 2009 Jun; 36(6):1170-9. PubMed ID: 19411387
[TBL] [Abstract][Full Text] [Related]
15. Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden.
Kalkan A; Hallert E; Bernfort L; Husberg M; Carlsson P
Rheumatology (Oxford); 2014 Jan; 53(1):153-60. PubMed ID: 24136064
[TBL] [Abstract][Full Text] [Related]
16. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
[TBL] [Abstract][Full Text] [Related]
17. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
18. [Medical and economic aspects of rheumatoid arthritis].
Fautrel B; Gaujoux-Viala C
Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
[TBL] [Abstract][Full Text] [Related]
19. Evolution of cost structures in rheumatoid arthritis over the past decade.
Huscher D; Mittendorf T; von Hinüber U; Kötter I; Hoese G; Pfäfflin A; Bischoff S; Zink A;
Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
[TBL] [Abstract][Full Text] [Related]
20. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
